AWAndrew Wagner

Andrew Wagner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrew Wagner has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS Q61R Human Endothelial Cells

    by Sara Alharbi, Andrew Wagner, Svatava Merkle, Patricia Pastura, C. Griffin McDaniel, Dermot Fox, Yan Xu, Timothy D. Le Cras

    Background: An activating NRAS p .Q61R ( NRAS Q61R ) somatic mutation occurs in the lesions of patients with kaposiform lymphangiomatosis (KLA). Therapies for KLA patients are limited and since the mitogen‐activated protein kinase pathway is hyperactivated by NRAS Q61R , we evaluated the potency of Mitogen‐activated protein kinase kinase (MEK) inhibitors (trametinib, selumetinib, and cobimetinib) on human NRAS Q61R endothelial cells (ECs). RNA sequencing analysis was performed to identify dysregulated genes and those restored by trametinib. Trametinib was tested in a mouse xenograft model of NRAS Q61R ECs. Procedure: Doxycycline (Dox)‐inducible NRAS Q61R ECs were treated with trametinib, selumetinib, cobimetinib, or vehicle (control). Cell signaling pathways, proliferation, migration, morphology, and angiopoietin‐2 (ANG‐2) levels were assessed. RNA‐sequencing analysis was performed on Dox‐induced NRAS wild‐type ( NRAS WT ), NRAS Q61R , and trametinib‐treated NRAS Q61R ECs. Selected proteins were verified by immunoblotting. NRAS Q61R ECs were injected into nude mice on Dox‐containing diet to generate xenografts and treated with trametinib or vehicle. Results: Trametinib reduced NRAS Q61R ‐activated ERK phosphorylation, cell proliferation, migration, spindling, and ANG‐2 at lower doses than selumetinib or cobimetinib. RNA‐sequencing detected 1315 upregulated and 1773 downregulated genes in NRAS Q61R ECs compared with NRAS WT . Trametinib corrected 19% upregulated and 8% downregulated genes, including elevated Notch ligands (DLL4, JAG1), activated Notch 1, and HES1. Trametinib reduced NRAS Q61R ECs xenograft weights by 46%, vascular area by 63%, and phosphorylated ERK staining. Conclusion: Trametinib was the most effective MEK inhibitor, correcting some dysregulated genes in NRAS Q61R ECs, including some in the Notch pathway. Trametinib reduced vessel overgrowth in xenografts of NRAS Q61R ECs. These studies support using trametinib treatment for KLA patients with an NRAS Q61R mutation.


  • Open Access

    Decoding Lymphangioleiomyomatosis (LAM) Niche Environment via Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics

    by Ken Chen, Shuyang Zhao, Minzhe Guo, Hasan Reza, Andrew Wagner, Adnan Cihan Cakar, Cheng Jiang, Erik Zhang, Jenna Green, Emily Martin, et al.

    Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease characterized by cystic destruction and metastatic growth of smooth muscle-like cells. Despite advances in understanding its genetic basis, the cellular heterogeneity, regulatory mechanisms, and microenvironmental interactions driving LAM progression remain poorly defined. In this study, we employed an integrative multi-omics approach combining single-cell RNA sequencing (scRNA-seq), single-nucleus ATAC sequencing (snATAC-seq), and high-resolution spatial transcriptomics (Visium, Visium HD, and Xenium) to decode the LAM niche in its native environment. We identified two spatially and functionally distinct LAM subtypes: LAM CORE1 and LAM CORE2 . LAM CORE1 cells exhibited a uterine smooth muscle-like phenotype, expressing associated markers ( ACTA2 , MYH11 ) and were enriched in MTORC1 signaling and myogenic pathways, supporting a uterine origin. In contrast, LAM CORE2 cells displayed fibroblast-like features, with upregulated extracellular matrix (ECM) remodeling genes ( COL1A1 , MMP11 ) and epithelial-to-mesenchymal transition (EMT) pathways, suggesting a role in niche formation. Pseudotime and regulon analyses revealed dynamic transitions between these subtypes, driven by distinct transcriptional networks (e.g., HOX/PBX in LAM CORE1 , TWIST/ZEB in LAM CORE2 ). The presence of the two distinct LAM subtypes was further validated by RNAscope and immunofluorescence microscopy. We identified LAM-associated fibroblasts (LAFs) as activated stromal cells expressing canonical markers ( FAP , S100A4 , VIM, IGFBP7, SPARC ) and localized within LAM lesions. Subpopulations of LAFs, LAF-seed (proximal to LAM CORE1 ) and LAF-niche (surrounding LAM niches), exhibited unique functional profiles, including ECM deposition, TGF-β signaling, and myofibroblast activation. Regulatory network analysis pinpointed EGR1 as a central hub governing LAF phenotype. Our comprehensive spatial profiling revealed niche structures dominated by LAM CORE1 cells and surrounded by lymphatic endothelial cells (LECs), LAFs, scattered LAM CORE2 cells, macrophages, and reprogrammed alveolar epithelial cells (AT2). ECM remodeling and aberrant organization of cable-like structures (α-smooth muscle actin+) of the LAM niches were further validated by second harmonic generation microscopy. These findings provide a high-resolution blueprint of LAM pathogenesis, highlighting the interplay between uterine-derived LAM CORE cells, activated fibroblasts, and the remodeled lung microenvironment. They significantly enhance our understanding of the LAM niche microenvironment and offer insights into potential therapeutic targets and strategies for managing this complex disease.


  • Open Access

    Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells

    by Tasnim Olatoke, Andrew Wagner, Aristotelis Astrinidis, Erik Y. Zhang, Minzhe Guo, Alan G. Zhang, Ushodaya Mattam, Elizabeth J. Kopras, Nishant Gupta, Eric P. Smith, et al.

    Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that predominantly affects women. LAM cells carry TSC1/TSC2 mutations, causing mTORC1 hyperactivation and uncontrolled cell growth. mTORC1 inhibitors stabilize lung function; however, sustained efficacy requires long-term administration, and some patients fail to tolerate or respond to therapy. Although the genetic basis of LAM is known, mechanisms underlying LAM pathogenesis remain elusive. We integrated single-cell RNA sequencing and single-nuclei ATAC-seq of LAM lungs to construct a gene regulatory network controlling the transcriptional program of LAM cells. We identified activation of uterine-specific HOX-PBX transcriptional programs in pulmonary LAM CORE cells as regulators of cell survival depending upon HOXD11-PBX1 dimerization. Accordingly, blockage of HOXD11-PBX1 dimerization by HXR9 suppressed LAM cell survival in vitro and in vivo. PBX1 regulated STAT1/3, increased the expression of antiapoptotic genes, and promoted LAM cell survival in vitro. The HOX-PBX gene network provides promising targets for treatment of LAM/TSC mTORC1-hyperactive cancers.


  • LIST OF Contributors

    by Robert G. Best, Vineet Bhandari, Jeffrey S. Dungan, Richard W. Erbe, James D. Goldberg, John Paul Govindavari, Anthony R. Gregg, Susan J. Gross, Jeffrey R. Gruen, Csilla Krausz, et al.